A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Phase

Division (Location)

Study ID

NCT#

Brief Description
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.